• Something wrong with this record ?

Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis

P. Grassi, L. Doucet, P. Giglione, V. Grünwald, B. Melichar, L. Galli, U. De Giorgi, R. Sabbatini, C. Ortega, M. Santoni, A. Bamias, E. Verzoni, L. Derosa, H. Studentova, M. Pacifici, J. Coppa, V. Mazzaferro, F. de Braud, C. Porta, B. Escudier,...

. 2016 ; 11 (4) : e0151662. [pub] 20160411

Language English Country United States

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc16027553

Pancreatic metastases from renal cell carcinoma are uncommon and their prognostic significance is not well defined. In this analysis we evaluated the outcome of patients with pancreatic metastases treated with either targeted therapies or local treatment to the pancreas. Patients with pancreatic metastases from renal cell carcinoma treated between 1993 and 2014 were identified from 11 European centers. Clinical records were retrospectively reviewed. Kaplan-Meier method and log-rank test were used to evaluate progression-free survival and overall survival. Cox's proportional hazard models were used for survival analysis. In total, 276 PM patients were evaluated, including 77 (28%) patients treated by either surgery or radiotherapy to the pancreas, and 256 (93%) who received systemic therapy. Median time from nephrectomy to diagnosis of pancreatic metastases was 91 months (IQR 54-142). Disease control rate after first-line TTs was 84%, with a median progression-free survival of 12 months (95% CI 10-14). Median overall survival was 73 months (95% CI 61-86) with a 5-year OS of 58%. Median OS of patients treated with local treatment was 106 months (95% CI 78-204) with a 5-year overall survival of 75%. On multivariable analysis, nephrectomy (HR 5.31; 95%CI 2.36-11.92; p<0.0001), Memorial Sloan Kettering/International Metastatic RCC Database Consortium prognostic score (HR 1.45, 95% CI 0.94-2.23 for intermediate vs good vs risk; HR 2.76 95%, CI 1.43-5.35 for poor vs good risk p = 0.0099) and pancreatic local treatment (HR 0.48; 95%CI 0.30-0.78 p = 0.0029) were associated with overall survival. Difference in median OS between patients with PM and that reported in a matched-control group of mRCC patients with extrapancreatic metastases was statistically significant (p < .0001). Pancreatic metastases from renal cell carcinoma usually occur years after nephrectomy, are associated with an indolent behavior and a prolonged survival. Targeted therapies and locoregional approaches are active and achieve high disease control rate.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027553
003      
CZ-PrNML
005      
20170427080549.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0151662 $2 doi
024    7_
$a 10.1371/journal.pone.0151662 $2 doi
035    __
$a (PubMed)27064898
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Grassi, Paolo $u Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy.
245    10
$a Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis / $c P. Grassi, L. Doucet, P. Giglione, V. Grünwald, B. Melichar, L. Galli, U. De Giorgi, R. Sabbatini, C. Ortega, M. Santoni, A. Bamias, E. Verzoni, L. Derosa, H. Studentova, M. Pacifici, J. Coppa, V. Mazzaferro, F. de Braud, C. Porta, B. Escudier, G. Procopio,
520    9_
$a Pancreatic metastases from renal cell carcinoma are uncommon and their prognostic significance is not well defined. In this analysis we evaluated the outcome of patients with pancreatic metastases treated with either targeted therapies or local treatment to the pancreas. Patients with pancreatic metastases from renal cell carcinoma treated between 1993 and 2014 were identified from 11 European centers. Clinical records were retrospectively reviewed. Kaplan-Meier method and log-rank test were used to evaluate progression-free survival and overall survival. Cox's proportional hazard models were used for survival analysis. In total, 276 PM patients were evaluated, including 77 (28%) patients treated by either surgery or radiotherapy to the pancreas, and 256 (93%) who received systemic therapy. Median time from nephrectomy to diagnosis of pancreatic metastases was 91 months (IQR 54-142). Disease control rate after first-line TTs was 84%, with a median progression-free survival of 12 months (95% CI 10-14). Median overall survival was 73 months (95% CI 61-86) with a 5-year OS of 58%. Median OS of patients treated with local treatment was 106 months (95% CI 78-204) with a 5-year overall survival of 75%. On multivariable analysis, nephrectomy (HR 5.31; 95%CI 2.36-11.92; p<0.0001), Memorial Sloan Kettering/International Metastatic RCC Database Consortium prognostic score (HR 1.45, 95% CI 0.94-2.23 for intermediate vs good vs risk; HR 2.76 95%, CI 1.43-5.35 for poor vs good risk p = 0.0099) and pancreatic local treatment (HR 0.48; 95%CI 0.30-0.78 p = 0.0029) were associated with overall survival. Difference in median OS between patients with PM and that reported in a matched-control group of mRCC patients with extrapancreatic metastases was statistically significant (p < .0001). Pancreatic metastases from renal cell carcinoma usually occur years after nephrectomy, are associated with an indolent behavior and a prolonged survival. Targeted therapies and locoregional approaches are active and achieve high disease control rate.
650    _2
$a karcinom z renálních buněk $x mortalita $x patologie $x terapie $7 D002292
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x mortalita $x patologie $x terapie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a cílená molekulární terapie $x mortalita $7 D058990
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a nefrektomie $x mortalita $7 D009392
650    _2
$a nádory slinivky břišní $x mortalita $x sekundární $x terapie $7 D010190
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Doucet, Ludovic $u Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France.
700    1_
$a Giglione, Palma $u Medical Oncology, IRCCS San Matteo University Hospital Foundation, Viale Camillo Golgi, 19, 27100, Pavia, Italy.
700    1_
$a Grünwald, Viktor $u Clinic for Haematology, Hemostasis, Oncology and Stemcelltransplantation, Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.
700    1_
$a Melichar, Bohuslav $u Dept of Oncology, Palacký University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Galli, Luca $u Medical Oncology 2, A.O.U.P., Istituto Toscano Tumori, via Roma 67, 56126, Pisa, Italy.
700    1_
$a De Giorgi, Ugo $u Dept of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, Italy.
700    1_
$a Sabbatini, Roberto $u Dept of Oncology and Haematology and Respiratory Disease, University Hospital, Via del Pozzo 71, 41124, Modena, Italy.
700    1_
$a Ortega, Cinzia $u Medical Oncology 1 - Candiolo Cancer Institute-FPO, IRCCS, Strada Provinciale, 142 km 3,95, 10060, Candiolo, Italy.
700    1_
$a Santoni, Matteo $u Medical Oncology, AOU Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, 71, 60126, Ancona, Italy.
700    1_
$a Bamias, Aristotelis $u Dept of Clinical Therapeutics, Alexandra General Hospital, V. Sofias and Lourou 1 11528, Athens, Greece.
700    1_
$a Verzoni, Elena $u Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy.
700    1_
$a Derosa, Lisa $u Medical Oncology 2, A.O.U.P., Istituto Toscano Tumori, via Roma 67, 56126, Pisa, Italy.
700    1_
$a Študentová, Hana, $u Dept of Oncology, Palacký University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20, Olomouc, Czech Republic. $d 1979- $7 xx0122256
700    1_
$a Pacifici, Monica $u Medical Statistics, Trial Center, Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy.
700    1_
$a Coppa, Jorgelina $u Gastrointestinal Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy.
700    1_
$a Mazzaferro, Vincenzo $u Gastrointestinal Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy.
700    1_
$a de Braud, Filippo $u Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy.
700    1_
$a Porta, Camillo $u Medical Oncology, IRCCS San Matteo University Hospital Foundation, Viale Camillo Golgi, 19, 27100, Pavia, Italy.
700    1_
$a Escudier, Bernard $u Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France.
700    1_
$a Procopio, Giuseppe $u Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 4 (2016), s. e0151662
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27064898 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20170427080909 $b ABA008
999    __
$a ok $b bmc $g 1165867 $s 952183
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 4 $d e0151662 $e 20160411 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options